

Mercedes Brunet Serra

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2328893/mercedes-brunet-serra-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38
papers

1,100
citations

16
h-index

33
g-index

41
ext. papers

1,454
ext. citations

4.2
avg, IF

3.62
L-index

#	Paper	IF	Citations
38	Getting immunosuppression just right: the role of clinical biomarkers in predicting patient response post solid organ transplantation. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 1-13	3.8	0
37	Monitoring of gene expression in tacrolimus-treated de novo renal allograft recipients facilitates individualized immunosuppression: Results of the IMAGEN study. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 3851-3862	3.8	0
36	A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2021 , 146, 87-94	7.5	2
35	Tacrolimus, Sirolimus and Everolimus Doses in HIV-Infected Solid-Organ Recipients, Requiring a Cobicistat-Based Antiretroviral Regimen: Report of Three Cases and Review. <i>Infectious Diseases and Therapy</i> , 2021 , 10, 1055-1064	6.2	1
34	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2021 , 43, 150-200	3.2	17
33	Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran. <i>Journal of Inherited Metabolic Disease</i> , 2021 , 44, 961-971	5.4	17
32	Tetracaine from urethral ointment causes false positive amphetamine results by immunoassay. <i>Clinical Toxicology</i> , 2021 , 59, 500-505	2.9	0
31	Early prognostic performance of miR155-5p monitoring for the risk of rejection: Logistic regression with a population pharmacokinetic approach in adult kidney transplant patients. <i>PLoS ONE</i> , 2021 , 16, e0245880	3.7	3
30	Advantages of plasmatic CXCL-10 as a prognostic and diagnostic biomarker for the risk of rejection and subclinical rejection in kidney transplantation. <i>Clinical Immunology</i> , 2021 , 229, 108792	9	0
29	Monitoring of Donor-Derived Cell-Free DNA by Short Tandem Repeats: Concentration of Total Cell-Free DNA and Fragment Size for Acute Rejection Risk Assessment in Liver Transplantation. <i>Liver Transplantation</i> , 2021 ,	4.5	2
28	MicroRNAs 155-5p, 122-5p, and 181a-5p Identify Patients With Graft Dysfunction Due to T Cell-Mediated Rejection After Liver Transplantation. <i>Liver Transplantation</i> , 2020 , 26, 1275-1286	4.5	4
27	Nuclear factor of activated T cells as potential pharmacodynamic biomarker for the risk of acute and subclinical rejection in de novo liver recipients. <i>Liver International</i> , 2020 , 40, 931-946	7.9	3
26	Measuring Intracellular Concentrations of Calcineurin Inhibitors: Expert Consensus from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Expert Panel. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 665-670	3.2	6
25	Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials. <i>Liver International</i> , 2020 , 40, 2476-2488	7.9	1
24	Meropenem population pharmacokinetics in patients with decompensated cirrhosis and severe infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3619-3624	5.1	1
23	Monitoring of miR-181a-5p and miR-155-5p Plasmatic Expression as Prognostic Biomarkers for Acute and Subclinical Rejection in Adult Liver Transplant Recipients. <i>Frontiers in Immunology</i> , 2019 , 10, 873	8.4	12
22	Role of age and comorbidities in mortality of patients with infective endocarditis. <i>European Journal of Internal Medicine</i> , 2019 , 64, 63-71	3.9	20

21	A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments. <i>Translational Psychiatry</i> , 2019 , 9, 177	8.6	17
20	Pharmacodynamic Monitoring of mTOR Inhibitors. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 160-167	3.2	5
19	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 261-307	3.2	163
18	Tofacitinib Halts Progression of Graft Dysfunction in a Rat Model of Mixed Cellular and Humoral Rejection. <i>Transplantation</i> , 2018 , 102, 1075-1084	1.8	10
17	Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. <i>Hepatology</i> , 2018 , 67, 1683-1694	11.2	83
16	Urinary miR-155-5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 2636-2650	3.8	36
15	Pharmacodynamics of T cell function for monitoring pharmacologic immunosuppression after allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2017 , 105, 497-505	2.3	4
14	Cyclosporine A in addition to standard ART during primary HIV-1 infection: pilot randomized clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 829-836	5.1	7
13	High proportion of CD95(+) and CD38(+) in cultured CD8(+) T cells predicts acute rejection and infection, respectively, in kidney recipients. <i>Transplant Immunology</i> , 2016 , 34, 33-41	1.7	8
12	Voriconazole and cobicistat-boosted antiretroviral salvage regimen co-administration to treat invasive aspergillosis in an HIV-infected patient. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1125-7 ^{5.1}	5.1	5
11	High frequency of central memory regulatory T cells allows detection of liver recipients at risk of early acute rejection within the first month after transplantation. <i>International Immunology</i> , 2016 , 28, 55-64	4.9	17
10	Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , 2016 , 38 Suppl 1, S1-20	3.2	57
9	T-Cell Cytokines as Predictive Markers of the Risk of Allograft Rejection. <i>Therapeutic Drug Monitoring</i> , 2016 , 38 Suppl 1, S21-8	3.2	10
8	Dose-escalation of the first-in human phase I/Ib study of ABTL0812, a novel antitumor drug inhibiting the Akt/mTOR pathway in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2585-2585	2.2	3
7	Development and validation of a UHPLC diode array detector method for meropenem quantification in human plasma. <i>Clinical Biochemistry</i> , 2014 , 47, 223-7	3.5	16
6	Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. <i>Transplantation</i> , 2010 , 89, 994-1000	1.8	34
5	The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 2269-76	4.3	69
4	Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. <i>Therapeutic Drug Monitoring</i> , 2009 , 31, 139-52	3.2	347

3	T-cell function monitoring in stable renal transplant patients treated with sirolimus monotherapy. <i>Molecular Diagnosis and Therapy</i> , 2007 , 11, 247-56	4.5	18
2	Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. <i>Transplantation</i> , 2006 , 81, 541-6	1.8	52
1	Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil. <i>Clinical Chemistry</i> , 2003 , 49, 1891-9	5.5	46